Redeye comments on the subscription price for the ongoing rights issue - which was set below Redeye'...
Elanders presented yet another solid report for Q4 2022, growing adjusted EBIT by 37% y/y.
Duearitys certifieringsorgan Intertek meddelade den 20 januari att Tinearity G1 kommer att erhålla C...
Lipigon aviserade under förra veckan positiva säkerhetsdata med Lipisense i klinisk fas I.
Redeye is positively surprised by today’s news that Alelion and Exide Technologies have started a di...
Good momentum for its leased-capacity business We remove Ovzon-3 from '23e as we turn more prudent 1...
Q4 report due on Thursday 16 February We expect net sales of SEK 67m, up 49% y-o-y New CEO to start ...
Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin a...
I november 2022 rapporterade AcouSort att bolaget ingått ett samarbete med ett globalt life science-...
Kraftig tillväxt till följd av höga investeringar i marknadsföring… Nettoomsättningen i kvartalet up...
Peptonic växer kraftigt i Q3 med 68 procent och visar på en tydlig resultatförbättring.
Redeye concludes that Q4 was more or less exactly in line with Redeye’s sales estimates – both for A...
Redeye provides a research update following Penneo’s updated 2022 EBITDA guidance, while preliminary...
Redeye comments on the new positive phase I data from the Lipisense trial.
Israeli-based mobile gaming company Playtika has today announced a proposal to Rovio board of direct...
Prelim. ARR of DKK 71m corresponds to 28% y-o-y growth New '22 adj.
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different...
